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Abstract:  Portal  vein  thrombosis  (PVT)  not  associated  with  hepatocellular  carcinom
considered  a  frequent  complication  of  liver  cirrhosis  but,  unlike  PVT  occurring  in  non
cirrhotic patients, very few data are available on its natural history and management.  The 
reduced portal blood flow velocity is the main determinant of PVT but, a
thromboses, multiple factors local and systemic, inherited or acquired often can concur with. 
PVT has a variety of clinical presentations ranging from asymptomatic to life
diseases like gastroesophageal bleeding or acute intes
Doppler ultrasound but computed tomography and magnetic resonance imaging are useful to 
study the extent of thrombosis and the involvement of the abdominal organs. The risk of 
bleeding  mainly  determined  by  the  pre
alterations  causes  concern  for  the  treatment  of  PVT  in  cirrhotic  patients.  To  date, 
anticoagulant therapy seems to be indicated only in patients awaiting liver transplantation. 
This review focuses on the defin
benefit from treatment of PVT and examines the pros and cons of the available treatments in 
terms of efficacy, monitoring and safety, providing also perspectives for future studies.
Introduction: Liver cirrhosis is the most frequent 
underlying disease in patients with non
thrombosis occurring in the portal vein (PVT). In a 
large autopsy series of patients with PVT, neoplasia 
was present in 67%, cirrhosis in 28% and in only 
5% of patients PVT was considered primitive
view  of  the  recent progress  in  the  knowledge  of 
pathogenetic mechanisms,  prognosis  and 
therapeutic  strategy  of  PVT  these  three  clinical 
conditions have to be considered separately
Hepatocellular  carcinoma  (HCC)  is  the  most 
frequent cause of PVT in cirrhosis, being
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Portal  vein  thrombosis  (PVT)  not  associated  with  hepatocellular  carcinom
considered  a  frequent  complication  of  liver  cirrhosis  but,  unlike  PVT  occurring  in  non
cirrhotic patients, very few data are available on its natural history and management.  The 
reduced portal blood flow velocity is the main determinant of PVT but, a
thromboses, multiple factors local and systemic, inherited or acquired often can concur with. 
PVT has a variety of clinical presentations ranging from asymptomatic to life
diseases like gastroesophageal bleeding or acute intestinal ischemia. It is usually diagnosed by 
Doppler ultrasound but computed tomography and magnetic resonance imaging are useful to 
study the extent of thrombosis and the involvement of the abdominal organs. The risk of 
bleeding  mainly  determined  by  the  presence  of  gastroesophageal  varices  and  clotting 
alterations  causes  concern  for  the  treatment  of  PVT  in  cirrhotic  patients.  To  date, 
anticoagulant therapy seems to be indicated only in patients awaiting liver transplantation. 
This review focuses on the definition of the subgroups of patients with cirrhosis that might 
benefit from treatment of PVT and examines the pros and cons of the available treatments in 
terms of efficacy, monitoring and safety, providing also perspectives for future studies.
Liver cirrhosis is the most frequent 
underlying disease in patients with non-neoplastic 
thrombosis occurring in the portal vein (PVT). In a 
ts with PVT, neoplasia 
was present in 67%, cirrhosis in 28% and in only 
s PVT was considered primitive
1. In 
progress  in  the  knowledge  of 
mechanisms,  prognosis  and 
therapeutic  strategy  of  PVT  these  three  clinical 
ve to be considered separately
2-6.
Hepatocellular  carcinoma  (HCC)  is  the  most 
frequent cause of PVT in cirrhosis, being present in 
up to 44% of cases
7 and it has alway
for when a new diagnosis of PVT is made.
This  review  deals  with  PVT  occurring  in 
patients with liver cirrhosis without HCC focusing 
on  the  necessity  and/or  the  opportunity  of 
management of this specific complication of liver 
disease.
Prevalence:  The  occurrence  of  PVT  in  cirrhotic 
patients  has  been increasingly  reported  in    recent 
years.   This  stems from the  different procedures 
utilized for diagnosis and the different settings of 
cirrhotic patients studied. The presence of PVT was 
0.6% when evaluated by old angiographic studies
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Portal  vein  thrombosis  (PVT)  not  associated  with  hepatocellular  carcinoma  is 
considered  a  frequent  complication  of  liver  cirrhosis  but,  unlike  PVT  occurring  in  non-
cirrhotic patients, very few data are available on its natural history and management.  The 
reduced portal blood flow velocity is the main determinant of PVT but, as in other venous 
thromboses, multiple factors local and systemic, inherited or acquired often can concur with. 
PVT has a variety of clinical presentations ranging from asymptomatic to life-threatening 
tinal ischemia. It is usually diagnosed by 
Doppler ultrasound but computed tomography and magnetic resonance imaging are useful to 
study the extent of thrombosis and the involvement of the abdominal organs. The risk of 
sence  of  gastroesophageal  varices  and  clotting 
alterations  causes  concern  for  the  treatment  of  PVT  in  cirrhotic  patients.  To  date, 
anticoagulant therapy seems to be indicated only in patients awaiting liver transplantation. 
ition of the subgroups of patients with cirrhosis that might 
benefit from treatment of PVT and examines the pros and cons of the available treatments in 
terms of efficacy, monitoring and safety, providing also perspectives for future studies.
and it has always to be searched 
for when a new diagnosis of PVT is made.
This  review  deals  with  PVT  occurring  in 
patients with liver cirrhosis without HCC focusing 
on  the  necessity  and/or  the  opportunity  of 
management of this specific complication of liver 
The  occurrence  of  PVT  in  cirrhotic 
patients  has  been increasingly  reported  in    recent 
years.   This  stems from the  different procedures 
utilized for diagnosis and the different settings of 
cirrhotic patients studied. The presence of PVT was 
ed by old angiographic studies
8, Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
4.4%  by  ultrasound
9 and  10%-12%  when  more 
sensitive  procedures,  i.e.  computed  tomography 
(CT) scan and magnetic resonance imaging (MRI) 
are used
10-11.
Moreover,  the  prevalence  of  PVT  increases 
with the age and severity of liver disease reaching 
15%  in  patients  awaiting  liver  transplantation
12-15
and  36%  in  explanted  liver  at  pathological 
examination
16.
Few studies have focused on the incidence of 
PVT.  The de novo thrombosis within one year, in 
patients with liver cirrhosis,  ranges from 7.4% to 
16%
10,17.
Etiopathogenesis: It is generally thought that liver 
cirrhosis leads to a progressive bleeding tendency 
because  of  the  complex  alteration  of  the  clotting 
system induced by liver failure but recent studies 
have demonstrated   that liver cirrhosis, causing  a 
reduced  synthesis  of  either  pro-coagulant  or 
anticoagulant  proteins  is  still  associated  with  a 
balanced equilibrium of the clotting system set at a 
lower  level
18-22.  A  series  of  acquired  or  inherited 
conditions can easily tilt  this equilibrium towards
either bleeding or thrombosis
23-27.
Epidemiological studies show a prevalence of 
venous  thrombosis  of  0.5%  - 1%
28-31 in  patients 
with  liver  cirrhosis  is  even  greater  than  in  the 
general  population,    whereas  patients  with  PVT 
have  an  elevated  risk  of  developing  venous  
thrombo-embolism outside the splanchnic system
32.
As  in  all  venous  thrombosis
33-34 the 
pathogenesis  of  PVT  in  non-cirrhotic
35-36 and  in 
cirrhotic patients
37 is multifactorial, even if not all 
known  risk  factors  can  be  studied  easily  in  this 
setting due to the impaired synthetic and metabolic 
ability of the liver. Congenital or acquired, local or 
systemic factors can interact causing reduction of 
blood  flow  velocity,  endothelial damage  and 
clotting unbalance
38 (Table 1).
In  patients  with  cirrhosis  the  derangement  of 
liver  architecture  leads  to  increased  intrahepatic 
vascular resistance, development of porto-systemic 
collateral circulation and splanchnic vasodilatation 
and  ultimately to  a  stagnation  of the  portal flow, 
which is considered the main predisposing factor to 
thrombosis.
Zocco et al have recently demonstrated that the 
portal  flow  velocity,  measured  by  Doppler 
ultrasound, is inversely correlated with the risk of 
PVT
17. Patients with portal flow velocity less than 
15cm/sec  have  an  incidence  of  PVT  of  47.  8% 
compared  to  2%  of  those  with  a  velocity  >  15 
cm/sec. According to most recent hypotheses blood 
stagnation  causes  initiation  of  venous  thrombosis 
through endothelial activation induced by hypoxia 
secondary  to  the  hemoglobin  desaturation
39.
Nevertheless,  only  about  15%  of  patients  with 
advanced  liver  disease develop  PVT,  so  all  other 
risk  factors  implicated  in  the  pathogenesis  of 
venous thrombosis have been searched for in these 
patients.
The age, sex of the patient and etiology of liver 
disease have not resulted as risk factors for PVT in 
patients with cirrhosis, even if a lower prevalence of 
PVT was reported in PSC and PBC candidates for 
liver transplantation
12.
Local  risk  factors  may  trigger  thrombosis  via 
endothelial  damage  as  abdominal  inflammatory 
diseases like diverticulitis, pancreatitis, cholangitis.  
Abdominal  surgical  interventions,  particularly 
portal-caval shunts and splenectomy, are associated 
with  PVT
40-41.  The  prevalence  of  other  surgical 
interventions was found higher in cirrhotic patients 
with PVT in one study
42 but not in others
10,43.
Previous  bleeding  episodes from 
gastroesophageal  varices
11 and  their  endoscopic 
treatment
42 resulted  as  the  main  endothelial  risk 
factors  for  PVT  and  the  coexistence  of  inherited 
thrombophilia  increases  this  risk
37.    It  has  been 
hypothesized that thrombosis develops because of 
the direct endothelial damage or of the bacteremia 
induced  by  the  procedures
45.  An  increased 
endotoxemia and  clotting  activation  have  been 
demonstrated in the portal blood that may trigger 
thrombotic process in these patients
46.
Local  ablative therapies, percutaneous ethanol 
injection and thermotherapy for HCC may induce 
thrombosis of portal branches close to the tumor
47-
49.
Table   1.  Pathogenetic factors of PVT in cirrhosis
Risk factors Associated factors
Blood flow: reduced portal flow velocity Abdominal surgery
Child-Pugh class
Previous  gastrointestinal bleeding
Low platelet count
Endothelial : abdominal inflammatory diseases, endoscopic 
variceal treatment, anti-tumoral ablative therapy
Clotting : FIIG20210A mutation, elevated levels factor VIIIMedit J Hemat Infect Dis 2009, 1(3), Open Journal System 
The G20210A mutation of the prothrombin is 
the  main  inherited  clotting  abnormality  that  has 
been  associated  with  PVT  development  in  liver 
cirrhosis with a prevalence ranging from 21.4% to 
29%  and an Odds ratio of 5.9
10,43-44.  In a recent 
study  high  levels  of  factor  VIII  have  been  found 
associated with the risk of PVT in patients without 
cirrhosis
50. The contribution of factor VIII to PVT 
in  patients  with  liver  cirrhosis  remains  to  be 
established  since  high  levels  of  factor  VIII  are 
present in the advanced liver disease.
The contribution of FVL, and antiphospho-lipid 
antibodies to the pathogenesis of PVT in cirrhosis 
remains  controversial. MTHFRTT677  mutation in 
the  absence  of    hyperhomocysteinemia  is  not 
considered  a  risk  factor  of  venous 
thromboembolism
43,51-54.  Likewise,  the  role  of 
inherited  natural  anticoagulant  deficiency 
(antithrombin, protein C and protein S) in PVT of 
patients with liver cirrhosis is difficult to establish
55. 
In fact, in these patients synthetic dysfunction of the 
liver  leads  to  a  significant  reduction  of  these 
proteins  and  an  inherited  deficiency  could  be 
suspected only in the presence of positive familial 
studies.
In rare cases of PVT associated with recurrent 
venous  thrombosis,  or  severe  presentation  with 
intestinal  infarction  an  underlying 
myeloproliferative disorder can be suspected
56.
Is  it  worthwhile  performing  a  complete 
thrombophilic work-up in the  presence of PVT in a 
cirrhotic patient?
The identification of one or more thrombophilic 
risk  factors  in  a  single  patient    is  interesting  for 
research purposes and it useful in the clinical setting 
to plan the length of anticoagulant therapy. In fact 
in patients with “strong” and persistent risk factors 
anticoagulation has to be prescribed lifelong.  In the 
subgroups  of  patients  with  cirrhosis  and  PVT  in 
which anticoagulation is indicated (see below) the 
presence  of  thrombophilia  justifies  a  protracted 
therapy.
Clinical  Presentation:  From  a  patho-physiologic 
standpoint,  PVT  aggravates  portal  hypertension 
with increasing blood flow through collateral veins, 
which in turn favours bleeding from the esophageal 
and gastric veins. Even if thrombosis mostly occurs 
in  the  main  portal  trunk  it  may  extend  to its 
intrahepatic  branches,  splenic  vein  and  into  the 
superior  mesenteric  vein,  leading  to  mesenteric 
ischemia  or  infarction,  often  lethal  in  these 
patients
10,57.  In  normal  subjects  the  reduction  of 
portal flow induced by PVT is compensated by the 
increase of  hepatic  arterial  flow  (hepatic  arterial 
buffer response) preventing the hypoxic damage. In 
advanced  liver  cirrhosis  the  occurrence  of 
thrombosis  is  not  adequately  counterbalanced  by 
arterial buffering
58.
Moreover, thrombosis of the smaller branches 
of  hepatic  and  portal  veins,  frequently  found  in 
autopsy  samples  of  cirrhotic  livers,  may  induce 
hepatocyte  apoptosis,  contributing  to  the  further 
deterioration of liver disease
16. 
Whereas  theoretically  the  occurrence  of  PVT 
may  worsen  either  liver  function  or  portal 
hypertension
59-60 the  outcome  of  the  cirrhotic 
patients  with  PVT  and  the  actual  impact  of  the 
thrombosis  on  the  natural  history  of  the  cirrhosis 
have not been investigated to date.
In  clinical  practice  the  influence  of  PVT  has 
been  evaluated  only in  the  setting  of  liver 
transplantation  where,  even  if  PVT  is  not 
considered  an  absolute  contraindication,  it 
represents  a  complex  challenge  for  the  hepatic 
surgeon  and  is  the  cause  of  increased  post-
transplantation morbidity and mortality
11-15.
PVT  can  have  a  variable  clinical  onset.  In  a 
study  of  79  cirrhotic  patients,  PVT  caused  
gastrointestinal  bleeding  in  39%  and    abdominal 
pain in 18%; seventy per cent of patients, admitted 
for  acute  abdominal  pain,  presented  intestinal 
infarction due to the involvement of mesenteric vein 
(Figure 1).
In 43% of cases PVT was a fortuitous finding 
during the scheduled ultrasound examination for the 
screening  of  hepatocellular  carcinoma
10.  In  the 
cirrhotic patients it may be difficult to establish the 
“age”  of  thrombosis  since  the  criteria  commonly 
used  in  non-cirrhotics  to  define  acute  or  chronic 
PVT (presence of collateral circulation, presence of 
signs of portal hyper-tension) are already features of 
the liver disease.
In the previous study
10  PVT developed in the 
portal  trunk  in  56%  of  cases  and  concomitant
involvement of mesenteric or splenic veins occurred 
in  29%.  Isolate thrombosis of intrahepatic portal 
branches or of splenic and mesenteric veins were 
present in less than 15% of cases. At the diagnosis, 
rarely is  the thrombus  occlusive and the features of 
portal  cavernoma  are  less  frequent  compared  to 
those  of  non-cirrhotic  patients,  21%  vs  50% 
respectively
10,61 (Figure 2).
This is probably due to the earlier diagnosis of 
PVT and the less pronounced thrombophilic state in 
patients with cirrhosis.
Nonetheless,  the  complete  occlusion  of  the 
mesenteric  vein  is  invariably  associated  with Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
intestinal ischemia or infarction and the presence of 
a splanchnic vein thrombosis has to be investigated 
in cirrhotic patients with acute abdominal pain.
Figure 1.  Acute small bowel ischemia due to ptal mesenteric 
vein thrombosis: see thickened bowel walls, mesenteric oedema 
and fluid effusion.
Figure 2. Portal vein cavernoma.
PVT  is  usually  diagnosed  by  abdominal 
ultrasound  with  pulsed  and  color  Doppler 
examination but this procedure has sensitivity and 
specificity in detecting the thrombus variable from 
66%  to  100%,  because  it  is  affected  both  by 
operator  expertise  and  patient  characteristics
62-63. 
Definitive  diagnosis  of  PVT  can  be  obtained  by 
MRI  and  CT  scan;  the  first  provides  a  better 
evaluation  of  the  extent  of  the  thrombosis 
particularly  in  the  mesenteric  vein,  reaching  a 
sensitivity and  specificity  of  98%  - 100%
64.  CT 
scan gives information not only of the extent of the 
thrombosis  and  the  development  of  collateral 
circulation  but  also  of the state  of the  abdominal 
organs  and  it  is  the  procedure  of  choice  when 
intestinal ischemia or hepatocellular carcinoma are 
suspected
65-66.  In  recent  studies  contrast-enhanced 
ultrasound
67 and  PET  CT  proved  useful  in 
discriminating  between  benign  or  malignant 
thrombosis
68.
Overall  in  the  presence  of  new  diagnosis  of 
PVT,  the extent of the thrombosis and the clinical 
features of the patient have to be investigated for a 
correct  evaluation  of  the  prognosis  and  of  the  
treatment.
Treatment: Studies in numerous series of patients 
with  non-cirrhotic  PVT  have  demonstrated  that 
anticoagulation is safe and effective and represents 
the therapy of choice
61,69-72.
Despite the high frequency of PVT in patients 
with liver cirrhosis, there are very few data on the 
treatment  in  this  setting
73-76 nor  have  the  recent 
guidelines on vascular liver disorders addressed this 
specific issue
6,77.
The  main  concerns  for  anticoagulation  in 
cirrhotics arise from the presence of a bleeding risk 
in these patients and the lack of evidence of a real 
clinical benefit from the therapy in patients with an 
advanced liver disease.
In  stable  conditions  the  bleeding  risk  arises 
mainly from the presence of portal hypertension, in 
fact  more  than  50%  of  these  patients have 
gastroesophageal  varices
78 and  anticoagulation 
therapy might worsen the severity and duration of 
bleeding episodes.
The  utility  of  the  PVT  treatment  has  been 
assessed  only  in  patients  awaiting  liver 
transplantation in  whom  the  presence of  a  partial 
PVT represents a cause of increased morbidity and 
mortality, while  a  complete  thrombosis  is  a 
definitive contraindication to transplantation.
In  a  preliminary  study  Francoz  et  al.
11
demonstrated that anticoagulation therapy achieved 
a partial or complete portal recanalisation in 42% of 
19 patients awaiting liver transplantation. In these 
patients  the  survival  rate  was  79%  after  OLT, 
similar  to  patients  without  PVT  and  significantly 
better  than  patients  with  complete  portal  vein 
occlusion (50%).
These data, even if necessitating confirmation 
in  larger  series  of  patients,  indicated  that  PVT Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
arising in patients listed for liver transplantation is 
an indication for anticoagulation therapy.
Since data available are not sufficient to make 
recommendation  on PVT treatment, the following 
suggestions  should  be  considered  advice  that  can 
help  in  clinical  practice.  The  choice  of  the  best 
management should be evaluated case by case, at 
least to date.
Is PVT treatment indicated outside the setting of 
the  patients  awaiting  liver  transplantation? The 
presence of acute abdominal pain, due to intestinal 
ischemia  for  progression  of  thrombosis  to  the 
mesenteric vein, represents an absolute indication to 
anticoagulation in the attempt to prevent intestinal 
infarction. However, there remains to be evaluated 
whether  the  presence  of  mesenteric  vein 
involvement  in  asymptomatic  patients  is  an 
indication for treatment. Considering the likelihood 
of progression of the thrombotic process and the life 
threatening  consequences    of  the  complete 
mesenteric vein occlusion, treatment is advisable.
It  is  useful,  for  clinical  purpose,  to  identify 
other  specific  groups  of  patients  in  whom  PVT 
treatment needs to be evaluated:
- asymptomatic patients with a compensated liver 
disease
This  group  of  patients  should  be  treated 
according to the criteria of non-cirrhotic PVT either 
to  prevent  long  term  complications  of  the 
thrombosis  or  not  to  preclude  a  future  liver 
transplantation option.  Moreover,  a  complete 
assessment  of  risk  factors  is  suggested  in  these 
patients  since  a  thrombophilic  state  other  than 
cirrhosis per se is likely.
- patients  presented  with  bleeding  from  portal 
hypertension
The  clinical  onset  with  gastroesophageal 
bleeding  of  PVT  should  not  be  considered  a 
contraindication to  an  anticoagulant  therapy since 
the thrombosis may have triggered the bleeding by 
worsening  portal  hypertension.  Preliminary  data 
show that in these patients anticoagulation therapy 
is safe if they are adequately treated for bleeding 
recurrence  by  medical  and  endoscopic 
prophylaxis
79. The delay in the treatment of PVT till 
esophageal  eradication  (median  time  4  months) 
does  not hamper the efficacy of the treatment.
In these  patients  an  intrahepatic shunt  (TIPS) 
could  be  considered  as  second  line  treatment 
because  it  can  achieve  the  repermeation  of  the 
vessel  and  concomitant  treatment  of  portal 
hypertensive  complications  when  endoscopic 
therapies have failed
80.
Lastly,  the  treatment  of  PVT  is  not  to  be 
recommended    in  patients  with  advanced  liver 
disease,  unsuitable  for  liver  transplantation,  since 
the  improvement  of  survival  is  unlikely  in  this 
setting. Nor  it is recommended in the presence of a 
well  established  cavernomatous  transformation  of 
portal  vein  in  the  absence  of  well  defined  risk 
factors.
Which is the most adequate bleeding prophylaxis 
in  patients  with  medium-high  risk  varices 
candidates    to  anticoagulation  therapy? Studies 
addressing the issue in patients with PVTare lacking 
and it is currently advisable to apply to this group of 
patients the guidelines for the primary prophylaxis 
of bleeding followed for patients without PVT
3 with 
certain  warnings.  Medical  prophylaxis  with  non 
selective beta-blockers is effective in only a portion 
of patients and has also the disadvantage of further 
reducing  the  portal  flow
81.  Endoscopic  treatment 
especially  sclerotherapy  is  demonstrated  effective 
as primary prophylaxis of variceal bleeding even if 
this  procedure may  be  a risk  factor for  PVT and 
may induce bleeding complications.
As  in  non-cirrhotic  PVT,    anticoagulation 
therapy  is  the  first  line  therapeutic  strategy  in 
patients  with liver cirrhosis. Two  main groups of 
drugs  are  available  to  this  purpose  Vitamin  K 
antagonists  (VKA),  acenocoumarol  and  warfarin, 
and heparins.
Francoz  et  al.
11 administered  five-day-therapy 
with  low  molecular  weight  heparin  (nandroparin 
5700  UI/day  subcutaneously)  followed  by 
acenocoumarol at adjusted doses to achieve an INR 
value of 2.0 – 3.0 to 19 patients with PVT awaiting 
liver  transplantation.    Eight  of  them  (42.1%) 
obtained recanalisation of portal vein and only one 
patient  had  upper  gastrointestinal  bleeding  from 
post ligation ulceration.
Amitrano  et  al.
79 treated  28  cirrhotic  PVT 
patients  with  enoxaparin  200/UI/Kg  /day 
subcutaneously obtaining a complete recanalisation 
of portal vein after six months in 33.3%, a partial 
recanalisation in 50% and no response in 16.7% of 
patients.  Further  12  patients  who  continued 
anticoagulation obtained complete recanalisation at 
a median time of 11 months (range 7-17 months), 
thus a complete response was achieved in 75% of 
patients. It is worth noting that half of the patients 
had  presented    variceal  bleeding  and  had  been 
submitted  to  variceal  endoscopic  eradication  by 
band  ligation  before  starting  anticoagulation 
(Figure 3).Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
Figure 3. Portal vein thrombosis (left panel); complete recanalisation after anticoagulant therapy (right panel).
The  number  of  platelets  did  not  change 
significantly  in  any patient  during anticoagulation 
treatment and only two patients complained of mild 
anemia due to portal hypertensive gastropathy.
Which  is  the  best  anticoagulant  therapy? In 
absence of comparative studies, the choice of the 
anticoagulant therapy has to rely on the following 
considerations:
-VKAs  administered  by  mouth  are  more 
acceptable by the patients but they need periodical 
dose-adjustments  by  INR  monitoring;  in  patients 
with advanced liver disease the INR value is often 
spontaneously close to  or above 2.0  considered  a 
therapeutic  range  for  anticoagulation.  Thus  INR 
value  as  currently  measured  is  inadequate  to 
monitor  anticoagulation  for  patients  with  severe 
liver  disease
21,82,  yet  other  methods  are 
foreseen
21,83.The  long  duration  of  anticoagulant 
effect  due  to  the  long  half  life  of  VKAs  could 
represent a further clinical disadvantage in the case 
of bleeding episode.
- LMWHs  have  completely  replaced 
unfractionated  heparins  since  they  have  the  same
efficacy and do not necessitate monitoring for dose 
adjustment
84.  Furthermore  the  fearful  heparin 
induced  thrombocytopenia  is  less  common  with 
LMWH and this may be useful in cirrhotic patients 
with low platelet count.
These  disadvantages  of  both  anticoagulation 
strategies  may  be  overcome  by  the  new  oral 
anticoagulant drugs such as thrombin inhibitors and 
anti factor Xa
85.
Currently  VKAs  may  represent  a  therapeutic 
option  in  patients  with  compensated  liver  disease 
who  require  long  term  anticoagulation.  LMWHs 
should be given to patients awaiting liver
transplantation  and  to  patients  with  a  more 
severe liver disease. 
Which  is  the  duration  of  anticoagulation? The 
current  guidelines  for  the  treatment  of  venous 
thromboembolism
86 can  be  applied  to  cirrhotic 
PVT.    After  an  initial  3-6  month  period  of 
anticoagulant therapy patients should be separated 
into  the following groups:
- patients who achieved a complete recanalisation 
can stop anticoagulant therapy in the absence of 
previous  thrombotic  events,  or  thrombopilic 
risk  factors.  They  should  be  followed 
periodically for PVT recurrence.
- patients  with  partial  recanalisation  or  with  a 
stable  partial  thrombosis  should  continue 
anticoagulant  therapy  if  candidates  for  or 
suitable for  future OLT in  order to  prevent a 
complete portal vein occlusion.
- patients  who  failed  to  achieve  any 
recanalisation  of  occlusive  PVT  should  stop 
anticoagulant therapy. Nevertheless, in patients 
with deep vein thrombosis of the limbs, residual 
or persistent thrombosis is considered as a risk 
factor  for  recurrence  requiring  long-life 
anticoagulation
87-88.  If  this  applies  to  the Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
patients  with  cirrhotic  PVT  needs  to  be 
evaluated in future follow-up studies. 
-    patients  with  recurrence  of  PVT  should  be 
considered for long-life anticoagulant therapy.
Local  and  systemic  thrombolysis  has  been 
utilized  in  the  setting  of  non-cirrhotic  venous 
thrombosis  and  only  rarely  in  cirrhosis  as  rescue 
therapy  but  high  rate  of  major  complications 
including bleeding has been reported
89-90.
So  this  therapeutic  approach  in  a  cirrhotic 
patient  with  PVT  should  be  reserved  only  in  the 
case  of patients with ongoing intestinal infarction 
not responsive to anticoagulation therapy.
Transjugular intrahepatic porto systemic shunt 
(TIPS) can be considered a second line treatment of 
PVT  in  patients  with  portal  hypertensive 
complications  not  controlled  by  the  common 
therapeutic  approach  particularly  in  patients 
awaiting  liver  transplantation.  In  preliminary 
experience  Senzolo  et  al.    reported  a  successful 
TIPS placement in a 69% of 13 cirrhotic patients 
with PVT
80. This procedure is technically feasible 
also in patient with cavernomatous transformation 
of portal vein
91-93 unless intrahepatic portal branches 
are patent.
Perspectives: Portal vein thrombosis is recognized 
as  one  of the  complications  of liver cirrhosis but 
many aspects still remain to be elucidated. The first 
is the impact of PVT on the natural history of liver 
cirrhosis  and  prospective  studies  addressing  this 
issue  are  warranted  and  to  identify  subgroups  of 
patients who could benefit  from  PVT treatment.
The best treatment option in terms of efficacy 
and safety has also to be established. Furthermore, 
which  anticoagulant  treatment,  the  duration  of 
therapy and the modality of monitoring need to be 
evaluated in future controlled trials.
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